Recursion Pharmaceuticals (RXRX) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 2[1], 5 Phase 1[2].
RXRX has 7 Form 4 insider filings recorded at the SEC in the past 30 days[4].
NCT07517198Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.